2011-11-14T13:03:52-08:00 2010-12-31 Metis Group LLC 14 PENN PLZ STE 1800 NEW YORK NY 101221800 990 2010-01-01 208735688 SOLVING KIDS CANCER INC SOLV 2125886624 598 MADISON AVENUE 6TH FLOOR NEW YORK NY 10022 SCOTT KENNEDY 2011-11-14 Stephen Cobell 9087669800 2010 2016-02-24 21:20:13Z 1007874 false false X WWW.SOLVINGKIDSCANCER.ORG X 2006 NY SOLVING KIDS CANCER INC IS DEDICATED TO FACILITATING THE DEVELOPMENT OF THERAPIES/TREATMENTS TO IMPROVE SURVIVORSHIP OF THE DEADLIEST CHILDHOOD CANCERS THROUGH AN INNOVATIVE AND AGGRESSIVELY FUNDED MODEL. 100% OF ALL PUBLIC DONATIONS ARE USED FOR THE ORGANIZATIONS PROGRAMMING RELATED TO ITS MISSION-THE DEVELOPMENT OF THERAPIES/TREATMENTS TO IMPROVE SURVIVORSHIP FOR CHILDREN WITH PEDIATRIC CANCER. ALL PROJECTS ARE MANAGED WITH A HANDS-ON APPROACH USING MILESTONES AND GOALS FOR FUNDING. THE ORGANIZATION UTILIZES NEW IDEAS FROM RESEARCHERS AND IMPLEMENTS THEM INTO NEW CLINICAL STUDIES FOR CHILDREN. THE ORGANIZATIONS OPERATING/NON-RESEARCH EXPENSES ARE UNDERWRITTEN BY THE BOARD OF DIRECTORS. 8 8 2 25 0 566468 686390 0 50959 25234 13348 19872 630775 731496 708378 510261 0 511407 326096 0 317234 353465 355811 1573250 1192168 -942475 -460672 4442880 3958711 161467 137970 4281413 3820741 SOLVING KIDS CANCER INC IS DEDICATED TO FACILITATING THE DEVELOPMENT OF THERAPIES/TREATMENTS TO IMPROVE SURVIVORSHIP OF THE DEADLIEST CHILDHOOD CANCERS THROUGH AN INNOVATIVE AND AGGRESSIVELY FUNDED MODEL. 100% OF ALL PUBLIC DONATIONS ARE USED FOR THE ORGANIZATIONS PROGRAMMING RELATED TO ITS MISSION-THE DEVELOPMENT OF THERAPIES/TREATMENTS TO IMPROVE SURVIVORSHIP FOR CHILDREN WITH PEDIATRIC CANCER. ALL PROJECTS ARE MANAGED WITH A HANDS-ON APPROACH USING MILESTONES AND GOALS FOR FUNDING. THE ORGANIZATION UTILIZES NEW IDEAS FROM RESEARCHERS AND IMPLEMENTS THEM INTO NEW CLINICAL STUDIES FOR CHILDREN. THE ORGANIZATIONS OPERATING/NON-RESEARCH EXPENSES ARE UNDERWRITTEN BY THE BOARD OF DIRECTORS. false false 657562 510261 IDENTIFIED, FUNDED AND MANAGED VARIOUS CANCER RESEARCH PROJECTS THAT ARE SPECIFIC TO REACHING PATIENTS TODAY AND POTENTIALLY LEAD TO CURATIVE TREATMENTS FOR THE FUTURE. THE PROJECTS ARE ALIGNED WITH OUR RESEARCH PROGRAM CRITERIA - FIRST-IN-CHILDREN, NOVEL, HIGH-IMPACT/HIGH REWARD, LOW TOXICITY, POTENTIAL FOR CLINICAL BENEFIT.THROUGH OUR PREVIOUS SUPPORT OF A PROGRAM TO IDENTIFY AGENTS AGAINST PEDIATRIC CANCER STEM CELLS, CLINICAL TRIALS WERE LAUNCHED AND SUPPORTED BY SKC USING THESE AGENTS IN CHILDREN'S HOSPITALS IN THE U.S. AND CANADA. PUTTING TOGETHER A BIOTECH COMPANY AND CHILDREN'S CANCER CENTERS, THE ORGANIZATION LAUNCHED A CLINICAL TRIAL USING A NOVEL IMMUNOTHERAPEUTIC FOR CHILDREN WHO HAVE FAILED STANDARD CHEMOTHERAPY IN THE U.S. CONTINUED TO LAY THE GROUNDWORK FOR BRINGING PROMISING NEW AGENTS FROM PHARMA/BIOTECH INDUSTRY FOR ADULTS TO BE STUDIED IN CHILDREN IN 2011. THROUGH, THE THERAPEUTIC DEVELOPMENT INITIATIVE RECEIVED AND REVIEWED 25 PROPOSALS FOR NEW RESEARCH PROGRAMS OF WHICH 4 MET OUR RESEARCH PROGRAM CRITERIA THAT CAN ULTIMATELY BE 4 NEW EXPERIMENTAL TREATMENT OPTIONS FOR CHILDREN WITH CANCER. 657562 true true false false false false false false false false true false false false true false true false false false false true false false true false false true false true false false false false false false false false false false false false false false false false false false false false false true 2 0 true 2 true false false false false false false false false true true false 0 false false false false false false false false false false false X 8 8 false false false false false false false true true false false false true true true true true true true true false false NY X X X SAME AS ABOVE 2125886624 As Listed New York NY 10022 WAYNE ROBINSON 1.00 X X 0 0 0 SCOTT KENNEDY 55.00 X 200000 0 25092 Renata Schiavo 1.00 0 0 0 JOHN LONDON 1.00 X X 0 0 0 JOHN CODLING 1.00 X 0 0 0 DAVID BLAUSTEIN 1.00 X 0 0 0 CHANNING STAVE 1.00 X X 0 0 0 ARI SPAR 1.00 X 0 0 0 200000 25092 1 false true false CREATE GROUP NYC LLC 20 RENWICK STREET NEW YORK NY 10013 Acting Dev. Provider 210867 1 686390 686390 0 25234 25234 0 0 0 0 296250 276378 19872 0 0 0 731496 19872 25234 223571 223571 0 286690 286690 0 225392 101889 100694 22809 0 58172 26468 26157 5547 0 38278 13549 22471 2258 4254 1506 2497 251 0 0 29565 29565 0 0 0 252868 252868 0 947 947 244 244 0 0 610 476 134 0 0 0 0 24047 24047 668 668 OTHER MISC EXP 3413 3413 MERCHANT FEES 6419 6419 MEALS & ENTERTAINMENT 5783 351 5432 Marketing 9436 9436 INDIRECT FUNDRAISING EXP 11884 11884 9927 9597 330 1192168 657562 217372 317234 370843 88592 3977972 3777773 200 130 0 0 0 0 0 0 78810 39085 53107 39725 0 0 0 0 40758 52491 4442880 3958711 6488 22970 154979 100000 15000 161467 137970 X 4172963 3754091 108450 66650 4281413 3820741 4442880 3958711 -460672 X true true true X false false X 13499 4749085 1248831 566468 686390 7264273 0 0 13499 4749085 1248831 566468 686390 7264273 5514846 1749427 3469 119859 50959 25234 199521 0 75180 19872 95052 7558846 X 0.00000 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 78810 39085 39725 39725 Deferred Revenue 15000 15000 731496 1192168 -460672 -460672 731496 731496 731496 1192168 1192168 1192168 North America Sch Attachd 286690 Check 1 false false false false false false false Golf Outing 191500 191500 57874 17254 Spring Celebration 104750 104750 64100 137150 296250 296250 121974 154404 276378 19872 true Jennerex Inc 201 Mission Street Suite 1380 San Francisco CA 94105 261730046 223571 0 Cancer Research Sch Attached 0 1 X X X false false false false false false false false false false SCOTT KENNEDY 200000 25092 225092 Form 990, Part VI, Line 19 Form 990, Part VI, Line 19: Other Organization Documents Publicly Available AUDITED FINANCIAL REPORTS ARE AVAILABLE TO THE PUBLIC THROUGH SKC'S WEBSITE. THE ORGANIZATION GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY IS AVAILABLE UPON REQUEST Form 990, Part VI, Line 12c Form 990, Part VI, Line 12c: Explanation of Monitoring and Enforcement of Conflicts THE ORGANIZATION DISTRIBUTES A CONFLICT OF INTEREST POLICY TO EACH BOARD MEMBER ANNUALY AT A BOARD OF DIRECTORS MEETING. EACH DIRECTOR READS AND DISCUSSES ANY QUESTIONS/ISSUES AND THEN SIGNS A STATEMENT THAY THEY HAVE READ THE POLICY, WILL ADHERE TO, AND MUST INFORM THE BOARD/ORGANIZATION OF ANY POTENTIAL CONFLICTS OF INTEREST.IT WOULD BE DETERMINED TO EXCUSE THE BOARD MEMBER FROM ANY DISCUSSION/INVOLVEMENT IN BOARD MATTERS INVOLVING A CONFLICT OF INTEREST. Form 990, Part VI, Line 11 Form 990, Part VI, Line 11: Form 990 Review Process FORM 990 IS REVIEWED BY THE FINANCE COMMITTEE. UPON AGREEMENT FORM 990 IS PRESENTED TO BOARD FOR FULL APPROVAL AND COMMENTS. Client Note 1 - Schedule to Form 990 , Schedule F, PartIIResearch Grant 1 - Screening of treatment candidates against tumor-initiating cells; Research Grant 2 - Clinical study of rapamycin + vinblastine in U.S. and Canada ped. cancer centers. Schedule to Form 990, Schedule I, Part II1, Section (h) Purpose of Grant Assistance - Cancer research, clinical trials for pediatric patients